Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine in Myelofibrosis
NCT00381693Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Aug 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelofibrosis (MF), sponsored by Mayo Clinic. Primary endpoint: Patients With Confirmed Response (Complete Remission or Partial Remission) at 4 months. Started Aug 2006; status: terminated.
02
Drugs
azacitidine
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT00381693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00381693.